Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

NCT00154388 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Life Threatening Diseases

Interventions

DRUG: Imatinib mesylate

Sponsor

Novartis Pharmaceuticals